Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
CRYPTO
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
TECHNOLOGY
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
HEALTH
Top Biotech Stocks to Buy for 2021
By Bret Jensen
Mar 2, 2021 9:41 AM EST
Latest News
PRESS RELEASES
Exelixis To Webcast Fireside Chats As Part Of Virtual Investor Conferences In June
By Business Wire
May 26, 2021 4:15 PM EDT
PRESS RELEASES
Exelixis Announces Phase 1b Results From Cohort 6 Of COSMIC-021 Trial In Patients With Metastatic Castration-Resistant Prostate Cancer
By Business Wire
May 24, 2021 4:05 PM EDT
PRESS RELEASES
Exelixis Expands Its Biotherapeutics Portfolio With Acquisition Of GamaMabs Pharma's First-in-Class Humanized Antibody Program Against A Novel Oncology Target
By Business Wire
May 4, 2021 8:00 AM EDT
PRESS RELEASES
Exelixis To Webcast Fireside Chats As Part Of Virtual Investor Conferences In May
By Business Wire
Apr 27, 2021 4:05 PM EDT
PRESS RELEASES
Exelixis To Release First Quarter 2021 Financial Results On Thursday, May 6, 2021
By Business Wire
Apr 22, 2021 4:05 PM EDT
PRESS RELEASES
Exelixis Announces U.S. FDA Accepts Investigational New Drug Application For XB002 In Patients With Advanced Solid Tumors
By Business Wire
Apr 5, 2021 8:00 AM EDT
PRESS RELEASES
Exelixis' Partner Ipsen Receives European Commission Approval For CABOMETYX® (cabozantinib) In Combination With OPDIVO® (nivolumab) As First-Line Treatment For Patients With Advanced Renal Cell Carcinoma
By Business Wire
Mar 31, 2021 1:01 AM EDT
PRESS RELEASES
Exelixis Announces Clinical Trial Collaboration And Supply Agreement With Merck KGaA, Darmstadt, Germany And Pfizer To Evaluate XL092 And Avelumab In Various Forms Of Locally Advanced Or Metastatic Urothelial Carcinoma
By Business Wire
Mar 18, 2021 8:00 AM EDT
PRESS RELEASES
Exelixis Enters Into Exclusive License Agreement With WuXi Biologics To Support Further Expansion Of Its Growing Oncology Biologics Pipeline
By Business Wire
Mar 8, 2021 8:00 AM EST
PRESS RELEASES
Exelixis To Webcast Fireside Chats As Part Of Virtual Investor Conferences In March
By Business Wire
Feb 25, 2021 4:05 PM EST
PRESS RELEASES
Exelixis To Webcast Virtual Fireside Chat As Part Of The SVB Leerink 10th Annual Global Healthcare Conference On February 26, 2021
By Business Wire
Feb 19, 2021 4:07 PM EST
PRESS RELEASES
Exelixis To Host Investor Briefing To Discuss Data Presented At The American Society Of Clinical Oncology's 2021 Genitourinary Cancers Symposium
By Business Wire
Feb 9, 2021 4:08 PM EST
PRESS RELEASES
Exelixis Announces Positive Findings At ASCO GU For CABOMETYX® (cabozantinib) In Patients With Brain Metastases From Renal Cell Carcinoma
By Business Wire
Feb 8, 2021 5:00 PM EST
PRESS RELEASES
Exelixis To Webcast Virtual Fireside Chat As Part Of The Guggenheim Healthcare Talks Oncology Day On February 11, 2021
By Business Wire
Feb 4, 2021 4:05 PM EST
PRESS RELEASES
Exelixis And Adagene Enter Into Collaboration And License Agreement To Develop Novel Masked Antibody-Drug Conjugate Therapies With Improved Safety And Efficacy Profiles
By Business Wire
Feb 1, 2021 8:00 AM EST
PRESS RELEASES
Exelixis To Release Fourth Quarter And Full Year 2020 Financial Results On Wednesday, February 10, 2021
By Business Wire
Jan 27, 2021 4:05 PM EST
PRESS RELEASES
Exelixis Announces Initiation Of Phase 1 Trial Evaluating XL102 As A Single Agent And In Combination With Other Anti-Cancer Agents In Patients With Advanced Or Metastatic Solid Tumors
By Business Wire
Jan 25, 2021 8:00 AM EST
PRESS RELEASES
Exelixis Announces U.S. FDA Approval Of CABOMETYX® (cabozantinib) In Combination With OPDIVO® (nivolumab) As A First-Line Treatment For Patients With Advanced Renal Cell Carcinoma
By Business Wire
Jan 22, 2021 1:10 PM EST
PRESS RELEASES
Exelixis To Present At The Virtual 39th Annual J.P. Morgan Healthcare Conference On January 11, 2021
By Business Wire
Jan 4, 2021 4:05 PM EST
HEALTH
Top Biotech Stocks to Buy for 2021
By Bret Jensen
Mar 2, 2021 9:41 AM EST
PRESS RELEASES
Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival In COSMIC-311 Phase 3 Pivotal Trial In Patients With Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer
By Business Wire
Dec 21, 2020 7:30 AM EST
PRESS RELEASES
Exelixis In-Licenses Aurigene's Novel CDK7 Inhibitor And Files Investigational New Drug Application For Phase 1 Clinical Trial In Advanced Solid Tumors
By Business Wire
Dec 7, 2020 8:00 AM EST
PRESS RELEASES
Exelixis Announces Partner Takeda Receives Approval In Japan For CABOMETYX® (cabozantinib) For The Treatment Of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy
By Business Wire
Nov 27, 2020 8:00 AM EST
PRESS RELEASES
Exelixis To Webcast Fireside Chats As Part Of Virtual Investor Conferences In December
By Business Wire
Nov 23, 2020 5:30 PM EST
